Core Viewpoint - The company has developed a lyophilized nasal spray influenza vaccine suitable for individuals aged 3 to 17, which simulates natural infection and induces both systemic and local mucosal immunity with a validity period of 10 months [1] Group 1: Product Details - The lyophilized nasal spray influenza vaccine is the only nasal spray live attenuated influenza vaccine in China, significantly improving vaccination compliance among recipients [1] - The liquid nasal spray influenza vaccine received production approval in August 2025, representing an upgrade from the lyophilized form, eliminating the need for reconstitution during use [1] Group 2: Regulatory and Global Context - The lyophilized nasal spray influenza vaccine is part of the World Health Organization's (WHO) Global Action Plan for Influenza Vaccines (GAP) [1]